Drug Discovery

Barcelona skyline
#Events #Lab automation #Lab technology #SLAS Europe

SLAS Europe reveals New Product Award finalists

SLAS has announced the finalists for its New Product Award, with the winners to be announced at the annual conference. The SLAS 2024 Europe Conference and Exhibition is heading back to Barcelona, 27-29 May, for its fifth annual European conference. It will feature scientific… Read More

#News

Organoid
#Drug discovery #Human disease models #Organoids #Preclinical development #Webinar

Discover how organoids bridge the gap between the lab and clinic

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM… Read More

Webinar date:
Supported by HUB Organoids
#News

#Amino acids #Artificial intelligence (AI) #Biochemistry #Contract Research Organisations (CROs) #Drug discovery #Webinar

Last chance to register: Using AI to overcome drug discovery challenges

Traditional drug discovery is time-consuming and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More

Webinar date:
Supported by FUJIFILM Wako
#News

Human heart
#AI #AstraZeneca #BenevolentAI #Collaboration #Drug discovery #Heart failure #Target identification

AI collaboration shows success for novel heart failure target  

AstraZeneca has added a novel target for heart failure to its discovery portfolio through its collaboration with BenevolentAI.  This novel target for heart failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca. This is the first target to be selected from the extended… Read More

#News

#Cell Science #Drug discovery

Webinar: rAAV Genome sequencing uncovers transgene integrity and packaging impurities – 13.05.2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will highlight how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca.  Viewers will hear how library preparation, assessed data… Read More

#Webinars

Human heart
#Clinical trials #Drug discovery #Heart failure

Heart failure drug to progress to Phase II trials

Cytokinetics has announced topline data from the Phase I study of cardiac myosin inhibitor CK-4021586 (CK-586), which met its primary and secondary objectives.   The data support the advancement of CK-586 to a Phase II clinical trial in patients with heart failure with preserved ejection fraction (HFpEF) which… Read More

#News

#Aardvark Therapeutics #Biotechnology #Drug discovery #Obesity

New podcast: A new paradigm of appetite and hunger

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Tien Lee, CEO… Read More

#News

Artificial Intelligence
#Amino acids #Artificial intelligence (AI) #Biochemistry #Contract Research Organisations (CROs) #Drug discovery #Webinar

Webinar: Accelerate drug discovery with AI Amino Acid Mapping

Traditional drug discovery is time-consuming and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More

Webinar date:
Supported by FUJIFILM Wako
#News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  A leading news story this week has been the announcement of positive Phase II… Read More

#News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

This week in drug discovery (6-10 May) 

News round-up for 6-10 May by DDW Multimedia Editor Megan Thomas. A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the… Read More

#News

Great British Pounds, Investment
#Drug discovery #Funding #Investment

UK drug discovery needs stronger funding effort, report shows 

Improvements to the ways medicines are discovered are essential for the future health of patients, a new report by Medicines Discovery Catapult (MDC) shows.   The State of the Discovery Nation (SODN) 2024: ‘Fostering a Dynamic, Sustainable Medicines Discovery Sector’ report states that the industry must… Read More

#News

#AI #Cancer research #Collaboration #Drug development #Lantern Pharma #Metabolic inhibitor #Oregon Therapeutics #Protein disulfide isomerase (PDI)

AI collaboration to optimise development of cancer inhibitor drug 

Lantern Pharma has entered a strategic AI-driven collaboration with French biotechnology company Oregon Therapeutics to optimise the development of its first-in-class protein disulfide isomerase (PDI)1 inhibitor drug candidate XCE853 in novel and targeted cancer indications.   Lantern will be leveraging its RADR AI platform to uncover biomarkers and… Read More

#Business & Investment #Cancer Research #News

#Clinical trials #Concussion #Drug discovery #Neuroscience

Q&A: Developments in concussion therapies

DDW Editor Reece Armstrong speaks to Michael Wyand, Chief Executive Officer/Director, Oxeia Biopharmaceuticals about the development of the company’s treatment for concussion (OXE103) and the current lack of effective therapies for brain injuries.   RA: Tell us how OXE103 works?   MW: OXE103 (ghrelin) is a 28 amino… Read More

#Exclusive Content

#Advanced Therapies #Drug discovery

Webinar: Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics – 02.05.2024

Successful development of advanced biotherapeutics relies on extensive characterisation and tight quality control. Characterising binding properties of complex biomolecules is a critical step. Biophysical data combined with functional assays are needed to predict efficacy and potency, optimise drug delivery, assess critical quality attributes, and improve biologics drug design. Traditional approaches… Read More

#Webinars

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Business #Contract Research Organisations (CROs) #Drug discovery

Gentronix receives King’s Award for international trade success  

UK-based Contract Research Organisation (CRO) Gentronix has received a King’s Award for Enterprise after achieving triple-figure revenue growth following rapid expansion in international markets.   The toxicology specialist based at Alderley Park recorded total growth of 239% in overseas earning over the past three years. In the same… Read More

#News